vs
Organogenesis Holdings Inc.（ORGO）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Organogenesis Holdings Inc.的季度营收约是Ultragenyx Pharmaceutical Inc.的1.1倍（$225.6M vs $207.3M），Organogenesis Holdings Inc.净利率更高（19.4% vs -62.0%，领先81.4%），Organogenesis Holdings Inc.同比增速更快（78.1% vs 25.9%），Organogenesis Holdings Inc.自由现金流更多（$34.8M vs $-100.8M），过去两年Organogenesis Holdings Inc.的营收复合增速更高（43.2% vs 38.0%）
Organogenesis Holdings Inc.是一家领先的再生医学企业，专注于开发、生产用于伤口护理、外科修复、运动医学和皮肤病领域的先进治疗产品，主要服务美国及部分国际市场的医疗机构与患者，提供经临床验证的医疗解决方案。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
ORGO vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $225.6M | $207.3M |
| 净利润 | $43.7M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 28.1% | -54.7% |
| 净利率 | 19.4% | -62.0% |
| 营收同比 | 78.1% | 25.9% |
| 净利润同比 | 469.5% | 3.5% |
| 每股收益（稀释后） | $0.31 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $225.6M | $207.3M | ||
| Q3 25 | $150.9M | $159.9M | ||
| Q2 25 | $101.0M | $166.5M | ||
| Q1 25 | $86.7M | $139.3M | ||
| Q4 24 | $126.7M | $164.6M | ||
| Q3 24 | $115.2M | $139.5M | ||
| Q2 24 | $130.2M | $147.0M | ||
| Q1 24 | $110.0M | $108.8M |
| Q4 25 | $43.7M | $-128.6M | ||
| Q3 25 | $21.6M | $-180.4M | ||
| Q2 25 | $-9.4M | $-115.0M | ||
| Q1 25 | $-18.8M | $-151.1M | ||
| Q4 24 | $7.7M | $-133.2M | ||
| Q3 24 | $12.3M | $-133.5M | ||
| Q2 24 | $-17.0M | $-131.6M | ||
| Q1 24 | $-2.1M | $-170.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 72.6% | — | ||
| Q4 24 | 75.5% | — | ||
| Q3 24 | 76.7% | — | ||
| Q2 24 | 77.6% | — | ||
| Q1 24 | 73.9% | — |
| Q4 25 | 28.1% | -54.7% | ||
| Q3 25 | 13.7% | -106.9% | ||
| Q2 25 | -12.5% | -64.8% | ||
| Q1 25 | -30.9% | -102.6% | ||
| Q4 24 | 8.1% | -74.3% | ||
| Q3 24 | 5.4% | -94.6% | ||
| Q2 24 | -10.7% | -79.1% | ||
| Q1 24 | -3.5% | -151.9% |
| Q4 25 | 19.4% | -62.0% | ||
| Q3 25 | 14.3% | -112.8% | ||
| Q2 25 | -9.3% | -69.0% | ||
| Q1 25 | -21.7% | -108.5% | ||
| Q4 24 | 6.1% | -80.9% | ||
| Q3 24 | 10.7% | -95.7% | ||
| Q2 24 | -13.1% | -89.5% | ||
| Q1 24 | -1.9% | -156.8% |
| Q4 25 | $0.31 | $-1.28 | ||
| Q3 25 | $0.11 | $-1.81 | ||
| Q2 25 | $-0.10 | $-1.17 | ||
| Q1 25 | $-0.17 | $-1.57 | ||
| Q4 24 | $0.05 | $-1.34 | ||
| Q3 24 | $0.09 | $-1.40 | ||
| Q2 24 | $-0.13 | $-1.52 | ||
| Q1 24 | $-0.02 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $93.7M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $300.1M | $-80.0M |
| 总资产 | $598.7M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $93.7M | $421.0M | ||
| Q3 25 | $63.7M | $202.5M | ||
| Q2 25 | $73.1M | $176.3M | ||
| Q1 25 | $110.0M | $127.1M | ||
| Q4 24 | $135.6M | $174.0M | ||
| Q3 24 | $94.3M | $150.6M | ||
| Q2 24 | $89.9M | $480.7M | ||
| Q1 24 | $88.6M | $112.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $62.3M | — | ||
| Q2 24 | $63.8M | — | ||
| Q1 24 | $65.2M | — |
| Q4 25 | $300.1M | $-80.0M | ||
| Q3 25 | $255.1M | $9.2M | ||
| Q2 25 | $233.2M | $151.3M | ||
| Q1 25 | $242.9M | $144.2M | ||
| Q4 24 | $262.9M | $255.0M | ||
| Q3 24 | $278.5M | $346.8M | ||
| Q2 24 | $263.5M | $432.4M | ||
| Q1 24 | $278.0M | $140.3M |
| Q4 25 | $598.7M | $1.5B | ||
| Q3 25 | $509.8M | $1.2B | ||
| Q2 25 | $461.1M | $1.3B | ||
| Q1 25 | $467.4M | $1.3B | ||
| Q4 24 | $497.9M | $1.5B | ||
| Q3 24 | $446.3M | $1.5B | ||
| Q2 24 | $443.2M | $1.6B | ||
| Q1 24 | $458.5M | $1.3B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.22× | — | ||
| Q2 24 | 0.24× | — | ||
| Q1 24 | 0.23× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $39.4M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $34.8M | $-100.8M |
| 自由现金流率自由现金流/营收 | 15.4% | -48.6% |
| 资本支出强度资本支出/营收 | 2.1% | 0.5% |
| 现金转化率经营现金流/净利润 | 0.90× | — |
| 过去12个月自由现金流最近4个季度 | $-24.5M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $39.4M | $-99.8M | ||
| Q3 25 | $3.1M | $-91.4M | ||
| Q2 25 | $-32.9M | $-108.3M | ||
| Q1 25 | $-19.9M | $-166.5M | ||
| Q4 24 | $10.9M | $-79.3M | ||
| Q3 24 | $8.7M | $-67.0M | ||
| Q2 24 | $4.7M | $-77.0M | ||
| Q1 24 | $-10.2M | $-190.7M |
| Q4 25 | $34.8M | $-100.8M | ||
| Q3 25 | $844.0K | $-92.7M | ||
| Q2 25 | $-36.5M | $-110.7M | ||
| Q1 25 | $-23.6M | $-167.8M | ||
| Q4 24 | $7.6M | $-79.5M | ||
| Q3 24 | $6.1M | $-68.6M | ||
| Q2 24 | $2.9M | $-79.0M | ||
| Q1 24 | $-12.4M | $-193.9M |
| Q4 25 | 15.4% | -48.6% | ||
| Q3 25 | 0.6% | -58.0% | ||
| Q2 25 | -36.1% | -66.5% | ||
| Q1 25 | -27.2% | -120.5% | ||
| Q4 24 | 6.0% | -48.3% | ||
| Q3 24 | 5.3% | -49.2% | ||
| Q2 24 | 2.2% | -53.7% | ||
| Q1 24 | -11.3% | -178.2% |
| Q4 25 | 2.1% | 0.5% | ||
| Q3 25 | 1.5% | 0.8% | ||
| Q2 25 | 3.6% | 1.5% | ||
| Q1 25 | 4.2% | 1.0% | ||
| Q4 24 | 2.7% | 0.1% | ||
| Q3 24 | 2.2% | 1.2% | ||
| Q2 24 | 1.4% | 1.4% | ||
| Q1 24 | 2.0% | 3.0% |
| Q4 25 | 0.90× | — | ||
| Q3 25 | 0.14× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.43× | — | ||
| Q3 24 | 0.71× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ORGO
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
